| 000 | 01510 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250513094743.0 | ||
| 264 | 0 | _c19960924 | |
| 008 | 199609s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(96)00490-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTcheng, J E | |
| 245 | 0 | 0 |
_aGlycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cAug 1996 |
||
| 300 |
_a35-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAtherectomy, Coronary |
| 650 | 0 | 4 | _aConstriction, Pathologic |
| 650 | 0 | 4 | _aEptifibatide |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xtherapeutic use |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aStents |
| 650 | 0 | 4 | _aTirofiban |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTyrosine _xanalogs & derivatives |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 78 _gno. 3A _gp. 35-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(96)00490-0 _zAvailable from publisher's website |
| 999 |
_c8748847 _d8748847 |
||